---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-010311"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:43:13.809550+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience enters into ATM equity offering program with Stifel and Cantor

## Summary
- Entered into sales agreement with Stifel and Cantor for at-the-market equity offering of common stock.
- Commission of 3.0% of gross proceeds payable to sales agents.
- Shares sold under existing shelf registration statement filed March 30, 2021.
- Company sets parameters including maximum shares, time period, and minimum price.
- Sales may be made on Nasdaq or in privately negotiated transactions.

## SEC filing metadata
- accession: 0001493152-23-010311
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315223010311/0001493152-23-010311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315223010311/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-010311
- JSON: https://secwatch.observer/filing/0001493152-23-010311.json
- Plain text: https://secwatch.observer/filing/0001493152-23-010311.txt

## Key facts
- Material Agreements
  Dare Bioscience, Inc. entered into Sales Agreement with Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. (effective 2023-03-31).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co.
  - Effective: 2023-03-31
  source text: On March 31, 2023, Daré Bioscience, Inc. (“we,” “us,” “our”), entered into a sales agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”) and Cantor Fitzgerald & Co. (“Cantor”) to sell shares of our common stock from time to time through an “at-the-market” equity offering program under which Stifel Nicolaus and Cantor will act as our sales agents (each individually a “Sales Agent” and together, the “Sales Agents”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315223010311/0001493152-23-010311-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.